Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 3Xerostomia 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Radiation Injuries 1Prevention of Colorectal Cancer 1Mucositis 1Lung Neoplasms 1Kidney Neoplasms 1Colorectal Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Nivolumab 11Specimen Handling 8Ipilimumab 7pembrolizumab 5CTLA-4 Antigen 5cabozantinib 4Magnetic Resonance Spectroscopy 4Biopsy 4Radiosurgery 3Axitinib 3pazopanib 2Sunitinib 2Everolimus 2Blood Specimen Collection 2tivozanib 1sodium-iodide symporter 1sitravatinib 1lenvatinib 1belzutifan 1aldesleukin 1Zoledronic Acid 1Tissue Banks 1Selenomethionine 1Radiotherapy 1Radiopharmaceuticals 1Nephrectomy 1Molecular Imaging 1Metastasectomy 1Inulin 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Clear-cell metastatic renal cell carcinoma × Selenomethionine × Clear all
NCT05363631 2025-12-10

Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

University of Iowa

Phase 1/2 Active not recruiting
55 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡